Chardan Capital Has Lowered Expectations for Lexeo Therapeutics (NASDAQ:LXEO) Stock Price

Lexeo Therapeutics (NASDAQ:LXEO) had its target price reduced by stock analysts at Chardan Capital from $22.00 to $20.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock.

A number of other analysts also recently weighed in on the stock. Royal Bank of Canada reduced their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a report on Tuesday, March 25th. Leerink Partners reduced their target price on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Monday, March 24th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Lexeo Therapeutics in a report on Tuesday, April 8th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $21.80.

Lexeo Therapeutics Trading Down 4.9%

Shares of LXEO stock opened at $2.69 on Tuesday. Lexeo Therapeutics has a 12-month low of $1.45 and a 12-month high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The stock’s 50-day moving average price is $3.06 and its 200-day moving average price is $5.06. The stock has a market capitalization of $89.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.27.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Monday, May 12th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.19). Equities research analysts predict that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently made changes to their positions in the business. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 15.3% during the 4th quarter. Janus Henderson Group PLC now owns 4,339,254 shares of the company’s stock valued at $28,508,000 after purchasing an additional 576,059 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in Lexeo Therapeutics during the 1st quarter valued at about $5,139,000. Vestal Point Capital LP grew its holdings in Lexeo Therapeutics by 41.2% during the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock valued at $7,896,000 after purchasing an additional 350,000 shares during the last quarter. Woodline Partners LP grew its holdings in Lexeo Therapeutics by 0.8% during the 4th quarter. Woodline Partners LP now owns 858,691 shares of the company’s stock valued at $5,650,000 after purchasing an additional 6,730 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in Lexeo Therapeutics by 102.5% during the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.